Online citations, reference lists, and bibliographies.
← Back to Search

Chemotherapy Of Malignant Pleural Mesothelioma

P. Bertino, M. Carbone, H. Pass
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background: Owing to worldwide use of asbestos during the past century, the global incidence of mesothelioma is still increasing. Although the outcome for patients remains poor, there has been definite progress in the systemic treatment of this disease within the past 5 years. Objective: By examining the clinical trials performed and the role of novel emerging agents, this review aims to provide an ‘expert opinion’ on evidences that validate chemotherapy as current ‘standard of care’ for inoperable mesothelioma. Methods: Relevant literature about clinical trials was reviewed using a PubMed search and other relevant data about novel therapeutic approaches both established and in development. Conclusion: The response rates achieved using chemotherapeutic treatments are higher than previous ones, and in the future may be improved by the use of combined and personalized therapies.
This paper references
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1517/14656566.5.12.2441
Current chemotherapeutic treatment of malignant pleural mesothelioma
A. Nowak (2004)
10.3747/CO.2007.132
Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185
R. Buckstein (2007)
10.1191/0269216302pm505xx
Radiotherapy for the palliation of high-volume pleural effusion in malignant mesothelioma: case report
Y. Chin (2002)
10.1016/J.JTCVS.2005.02.051
Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy.
J. Alvarez (2005)
10.1073/pnas.211026798
SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma
P. Cacciotti (2001)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1016/S0169-5002(07)70167-8
Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters.
B. Kroczynska (2006)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1016/S1556-0864(15)31534-3
Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition.
M. Carbone (2006)
10.1097/MCP.0b013e328302851d
Malignant mesothelioma 2008
M. Zervos (2008)
10.1158/0008-5472.CAN-04-4409
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
S. Wedge (2005)
10.1097/JTO.0b013e31817c73ec
Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
Paul Taylor (2008)
10.1097/01.JTO.0000283221.63767.BA
C5-06: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma
H. Kindler (2007)
10.1016/J.LUNGCAN.2004.08.005
Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.
D. Fennell (2005)
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
V. Ambrosini (2005)
10.1111/j.1600-0609.2008.01121.x
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
M. von Lilienfeld-Toal (2008)
Phase II trial of vinorelbine and oxaliplatin Chemotherapy of malignant pleural mesothelioma
DA Fennell (2009)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1097/JTO.0B013E31802F3813
Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment
J. Sørensen (2007)
10.1634/THEONCOLOGIST.6-4-363
Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
A. Hanauske (2001)
10.1158/0008-5472.CAN-04-1898
Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells
C. Hoang (2004)
10.3816/CCC.2005.N.030
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
P. Kupsch (2005)
10.1158/1078-0432.CCR-07-1388
Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts
P. Bertino (2008)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1093/AJE/KWH025
Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.
B. Price (2004)
10.1016/S0140-6736(95)90462-X
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
10.1136/thx.2006.069872
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed
P. Bertino (2007)
10.1093/ANNONC/MDL017
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
H. Richly (2006)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1158/1078-0432.CCR-1405-2
Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies
D. Coppola (2004)
10.1002/JSO.20458
Thalidomide in primary peritoneal mesothelioma
Ghanashyam Biswas (2006)
10.1200/JCO.2007.25.18_SUPPL.7526
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.1159/000092085
Prognostic Value of Pleural Fluid pH in Malignant Epithelial Mesothelioma after Talc Poudrage
Y. Aelony (2006)
Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach on the basis of preclinical research of human cancer cell lines.
Y. Chen (2003)
10.1067/MTC.2001.111176
The α folate receptor is highly activated in malignant pleural mesothelioma
R. Bueno (2001)
10.1016/J.LUNGCAN.2005.04.010
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
Limited effi cacy of imatinib mesylate in malignant mesothelioma: a Phase II trial
A Mathy (2005)
10.1007/s00280-006-0243-4
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
C. Porta (2006)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1200/JCO.2007.15.2868
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
G. Simon (2008)
The alpha folate receptor is highly activated in malignant pleural mesothelioma.
R. Bueno (2001)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1179/oeh.2003.9.3.206
Malignant Mesothelioma in Australia, 1945–2002
J. Leigh (2003)
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Malignant mesothelioma in Australia
A. Musk (2006)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1002/cncr.23617
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1111/j.1365-2559.2004.01928.x
The pathology associated with therapeutic procedures in malignant mesothelioma
R. Attanoos (2004)
10.1165/AJRCMB.26.2.4673
The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor.
P. Cacciotti (2002)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1074/JBC.M406696200
Induction of Stem Cell Factor/c-Kit/Slug Signal Transduction in Multidrug-resistant Malignant Mesothelioma Cells*
A. Catalano (2004)
10.1097/01.jom.0000091682.95314.01
Estimating the Induction Period of Pleural Mesothelioma From Aggregate Data on Asbestos Consumption
Markku Mikael Nurminen (2003)
10.1002/cncr.11405
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
Diffuse malignant mesothelioma of the pleural space and its management.
L. Zellos (2002)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
10.1136/thx.2007.085241
EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors
H. Kothmaier (2007)
10.1016/S0022-5223(19)34203-5
Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions.
D. L. Hartman (1993)
[Effective treatment of malignant pleural effusion: Thoracoscopic talcum pleurodesis and pleuro-peritoneal shunt].
Arnd S Boehle (1999)
Comparison of insuffl ated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions
DL Hartman (1993)
10.1053/J.SEMINONCOL.2004.03.036
Increasing tumor uptake of anticancer drugs with imatinib.
K. Pietras (2004)
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1055/S-2007-1024304
DIE EFFEKTIVE BEHANDLUNG DES MALIGNEN PLEURAERGUSSES : THORAKOSKOPISCHE TALKUMPLEURODESE - PLEUROPERITONEALER SHUNT
Andreas Böhle (2008)
10(1) as fi rst-line therapy in malignant pleural mesothelioma
(2005)
• The fi rst demonstration that mesothelioma in vitro cultured cells display the same chemo-resistance when injected in SCID mice
P Bertino (2008)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1093/ANNONC/MDJ073
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
M. O'Brien (2006)
10.1016/J.LUNGCAN.2007.09.018
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
S. Kalmadi (2008)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar